J&J Cuts Deal With US Over Risperdal Marketing Fraud

Law360, San Diego (August 9, 2011, 9:54 PM EDT) -- Johnson & Johnson revealed Tuesday that it had reached an agreement in principle that may resolve a single misdemeanor criminal charge over its marketing practices for antipsychotic drug Risperdal.

New Brunswick, N.J.-based J&J said in a regulatory filing that U.S. prosecutors had been reviewing its sales and marketing activities related to Risperdal, including the alleged promotion of the drug for off-label uses, and that the U.S. Department of Justice and the U.S. Attorney’s Office for the Eastern District of Pennsylvania were continuing to pursue both criminal...
To view the full article, register now.